The deal expands Evotec's existing CRISPR licenses through the Broad Institute and adds to ERS's list of licensees for its gene editing technology.
The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.
Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.
The partners' first project will involve using Cellectis' TALEN gene editing technology to create virus-resistant human cells.
CBS News' 60 Minutes dives into CRISPR gene editing and how it could be used to treat disease.
In an essay at Foreign Affairs, University of Pennsylvania researchers discuss how to best regulate CRISPR gene editing.
In PNAS this week: splicing patterns within triple-negative breast cancer, new flySAM tool, and more.
In Nature this week: sequencing and phenotyping of more than 1,000 Saccharomyces cerevisiae isolates, and more.
Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.
In PNAS this week: ties between immunity and growth patterns in children, gene regulation in Acrobeloides nanus, and more.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.